Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.  Presenters:  Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) Co-Chair, Scientific Review Committee, VICC Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee Jonathan Ticku, MD Medical Oncologist and Hematologist GU Oncology Lead, Mayo Clinic Health System Assistant Professor of Oncology, Mayo Clinic La Crosse, Wisconsin Link to full program: https://bit.ly/4u0xH6q Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.